Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 9/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867923 | 0.83 | ALDH1A1 (0.40) | ALDH1A1PARP1PDPK1SMN1; SMN2CA12 | |
| SCHEMBL24783219 | 0.69 | ALDH1A1 (0.35) | ALDH1A1PARP1PDPK1SMN1; SMN2CA12 | |
| SCHEMBL3245216 | 0.65 | ALDH1A1 (0.39) | ALDH1A1PARP1PDPK1SMN1; SMN2CA12 | |
| SCHEMBL29561093 | 0.65 | ALDH1A1 (0.39) | ALDH1A1PARP1PDPK1SMN1; SMN2CA12 | |
| SCHEMBL142922 | 0.64 | QTRT1 (0.42) | DYRK1AXDHPNP | |
| SCHEMBL14793587 | 0.64 | ALDH1A1 (0.38) | ALDH1A1PARP1PDPK1SMN1; SMN2CA12 | |
| SCHEMBL14793621 | 0.64 | HPGD (0.38) | ALDH1A1PARP1PDPK1SMN1; SMN2CA12 | |
| SCHEMBL4455591 | 0.64 | — | — | |
| SCHEMBL2790086 | 0.62 | TDP1 (0.31) | LMNA | |
| SCHEMBL5110684 | 0.62 | MAPT (0.38) | PARP1AURKAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| US-11814407-B2 | Multiple coupling and oxidation method | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2023-11-14 | — | — | US | claimed |
| US-20230257413-A1 | ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | RIKEN GENESIS CO., LTD. (JP) | 2023-08-17 | — | — | US | claimed |
| EP-4219517-A1 | NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | Riken Genesis Co., Ltd. (JP) | 2023-08-02 | — | — | EP | claimed |
| CN-116322706-A | Novel artificial nucleic acid, method for producing same, and use thereof | 株式会社理真思 | 2023-06-23 | — | — | CN | claimed |
| CN-115677810-A | Double-stranded oligonucleotide, composition containing double-stranded oligonucleotide, conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-113646007-A | Novel artificial nucleic acid, method for producing same, and use thereof | 希森美康株式会社 | 2021-11-12 | — | — | CN | claimed |
| US-11142545-B2 | Synthesis of thiolated oligonucleotides without a capping step | BIOGEN MA INC. (US) | 2021-10-12 | — | — | US | claimed |
| US-11001602-B2 | Diarylsulfide backbone containing photolabile protecting groups | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2021-05-11 | — | — | US | claimed |
| US-10947262-B2 | Hydrophobic interaction chromatography for purification of oligonucleotides | BIOGEN MA INC. (US) | 2021-03-16 | — | — | US | claimed |
| US-4999428-A | Process for preparing cyclopentyl purine derivatives | SCHERING CORPORATION (US) | 1991-03-12 | — | — | US | claimed |
| EP-0412995-A1 | CYCLOPENTYL PURINE DERIVATIVES, INTERMEDIATES AND PROCESSES FOR PREPARATION | SCHERING CORPORATION (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0253412-B1 | N-PHOSPHONYLMETHOXYALKYL DERIVATIVES OF PYRIMIDINE AND PURINE BASES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM WITH ANTIVIRAL ACTIVITY | Ceskoslovenska akademie ved (CS) | 1990-10-31 | — | — | EP | claimed |
| EP-0339842-A2 | Novel oligoribonucleotide derivatives and application thereof to antiviral agents | ISIS PHARMACEUTICALS, INC. (US) | 1989-11-02 | — | — | EP | claimed |
| WO-1989010367-A1 | CYCLOPENTYL PURINE DERIVATIVES, INTERMEDIATES AND PROCESSES FOR PREPARATION | SCHERING CORPORATION (US) | 1989-11-02 | — | — | WO | claimed |
| EP-0338842-A1 | Cyclopentyl purine derivatives, intermediates and processes for preparation | SCHERING CORPORATION (US) | 1989-10-25 | — | — | EP | claimed |
| EP-0278501-A2 | Nucleotide analogs, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-08-17 | — | — | EP | claimed |
| EP-0253412-A2 | N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity | Ceskoslovenska akademie ved (CS) | 1988-01-20 | — | — | EP | claimed |
| EP-0236935-A2 | Carboxylic purine nucleosides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-16 | — | — | EP | claimed |
| EP-0219838-A2 | Carbocyclic purine nucleosides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257413-A1 | ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | NSUN2, NSUN3, POLRMT | ALDH1A1 986/4885PARP1 556/4885PDPK1 4329/4885 |
| US-11001602-B2 | Diarylsulfide backbone containing photolabile protecting groups | CRY2, PRXL2A, MGMT | ALDH1A1 1217/4885PARP1 2517/4885PDPK1 3811/4885 |
| US-11814407-B2 | Multiple coupling and oxidation method | RNGTT, PCNA, TYMP | ALDH1A1 932/4885PARP1 361/4885PDPK1 2115/4885 |
| US-10947262-B2 | Hydrophobic interaction chromatography for purification of oligonucleotides | IPO5, IPO4, PHAX | ALDH1A1 4330/4885PARP1 1981/4885PDPK1 4820/4885 |
| US-11142545-B2 | Synthesis of thiolated oligonucleotides without a capping step | RNGTT, NSUN3, NSUN2 | ALDH1A1 2661/4885PARP1 1750/4885PDPK1 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.